Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies

RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for...

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year   RICHLAND, WASHINGTON – February 12, 2019 — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Blu Build Featured on WCIV-TV in Charleston, SC

Blu Build Featured on WCIV-TV in Charleston, SC

WCIV-TV reports on the world’s first use of the Blu Build Cesium-131 brachytherapy delivery system at Hollings Cancer Center. Here’s the story on this important medical advance for prostate cancer patients and the doctors who treat...